source
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.BioSpace · 12d ago↗ source
- STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head studyEli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.STAT · 12d ago↗ source
- Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight lossEli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expect…